- Home
- KPTI vs FOA Comparison
KPTI vs FOA Comparison
Compare KPTI & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- FOA
- Stock Information
- Founded
- KPTI 2008
- FOA 2013
- Country
- KPTI United States
- FOA United States
- Employees
- KPTI N/A
- FOA N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- FOA Finance Companies
- Sector
- KPTI Health Care
- FOA Finance
- Exchange
- KPTI Nasdaq
- FOA Nasdaq
- Market Cap
- KPTI 103.5M
- FOA 240.8M
- IPO Year
- KPTI 2013
- FOA N/A
- Fundamental
- Price
- KPTI $0.64
- FOA $25.24
- Analyst Decision
- KPTI Strong Buy
- FOA Hold
- Analyst Count
- KPTI 4
- FOA 1
- Target Price
- KPTI $5.00
- FOA $24.00
- AVG Volume (30 Days)
- KPTI 1.0M
- FOA 155.6K
- Earning Date
- KPTI 11-05-2024
- FOA 11-06-2024
- Dividend Yield
- KPTI N/A
- FOA N/A
- EPS Growth
- KPTI N/A
- FOA N/A
- EPS
- KPTI N/A
- FOA 10.89
- Revenue
- KPTI $148,442,000.00
- FOA $719,526,000.00
- Revenue This Year
- KPTI $6.67
- FOA N/A
- Revenue Next Year
- KPTI $8.58
- FOA N/A
- P/E Ratio
- KPTI N/A
- FOA $2.01
- Revenue Growth
- KPTI 1.77
- FOA 3011.46
- 52 Week Low
- KPTI $0.63
- FOA $4.10
- 52 Week High
- KPTI $1.95
- FOA $28.50
- Technical
- Relative Strength Index (RSI)
- KPTI 25.28
- FOA 57.61
- Support Level
- KPTI $0.75
- FOA $23.46
- Resistance Level
- KPTI $0.83
- FOA $28.50
- Average True Range (ATR)
- KPTI 0.05
- FOA 2.70
- MACD
- KPTI -0.01
- FOA -0.01
- Stochastic Oscillator
- KPTI 4.21
- FOA 54.06
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.